GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » China Resources Boya Bio-pharmaceutical Group Co Ltd (SZSE:300294) » Definitions » Return-on-Tangible-Asset

China Resources Boya Bio-pharmaceutical Group Co (SZSE:300294) Return-on-Tangible-Asset : 8.16% (As of Mar. 2025)


View and export this data going back to 2012. Start your Free Trial

What is China Resources Boya Bio-pharmaceutical Group Co Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. China Resources Boya Bio-pharmaceutical Group Co's annualized Net Income for the quarter that ended in Mar. 2025 was ¥558 Mil. China Resources Boya Bio-pharmaceutical Group Co's average total tangible assets for the quarter that ended in Mar. 2025 was ¥6,833 Mil. Therefore, China Resources Boya Bio-pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 8.16%.

The historical rank and industry rank for China Resources Boya Bio-pharmaceutical Group Co's Return-on-Tangible-Asset or its related term are showing as below:

SZSE:300294' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 3.29   Med: 8.19   Max: 16.03
Current: 5.25

During the past 13 years, China Resources Boya Bio-pharmaceutical Group Co's highest Return-on-Tangible-Asset was 16.03%. The lowest was 3.29%. And the median was 8.19%.

SZSE:300294's Return-on-Tangible-Asset is ranked better than
88.09% of 1494 companies
in the Biotechnology industry
Industry Median: -36.61 vs SZSE:300294: 5.25

China Resources Boya Bio-pharmaceutical Group Co Return-on-Tangible-Asset Historical Data

The historical data trend for China Resources Boya Bio-pharmaceutical Group Co's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Boya Bio-pharmaceutical Group Co Return-on-Tangible-Asset Chart

China Resources Boya Bio-pharmaceutical Group Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.12 6.34 6.31 3.29 5.58

China Resources Boya Bio-pharmaceutical Group Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.09 8.62 5.03 -0.86 8.16

Competitive Comparison of China Resources Boya Bio-pharmaceutical Group Co's Return-on-Tangible-Asset

For the Biotechnology subindustry, China Resources Boya Bio-pharmaceutical Group Co's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Boya Bio-pharmaceutical Group Co's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, China Resources Boya Bio-pharmaceutical Group Co's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where China Resources Boya Bio-pharmaceutical Group Co's Return-on-Tangible-Asset falls into.


;
;

China Resources Boya Bio-pharmaceutical Group Co Return-on-Tangible-Asset Calculation

China Resources Boya Bio-pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=396.992/( (7433.752+6791.43)/ 2 )
=396.992/7112.591
=5.58 %

China Resources Boya Bio-pharmaceutical Group Co's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2025 )  (Q: Dec. 2024 )(Q: Mar. 2025 )
=557.936/( (6791.43+6875.106)/ 2 )
=557.936/6833.268
=8.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2025) net income data.


China Resources Boya Bio-pharmaceutical Group Co  (SZSE:300294) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


China Resources Boya Bio-pharmaceutical Group Co Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of China Resources Boya Bio-pharmaceutical Group Co's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Boya Bio-pharmaceutical Group Co Business Description

Traded in Other Exchanges
N/A
Address
Number 333, Huiquan Road, High-tech Industrial Park, Jiangxi Province, Fuzhou, CHN, 344000
China Resources Boya Bio-pharmaceutical Group Co Ltd is a China-based medical industry group that integrates biochemical drugs, chemical drugs, and active pharmaceutical ingredients. It is engaged in the provision of medical and health products and services. The product categories of the company include blood products, biochemical drugs, chemical medicines and others. Some of the company's blood products include human albumin, rabies immunoglobulin, intravenous human immunoglobulin and human fibrinogen.
Executives
Liang Xiao Ming Directors, executives
Li Shou Sun Executives
Zhang Shi Fang Executives
Tu Yan Shi Directors, executives
Chen Bing Executives
Liao Xin Xi Directors, executives
Fan Yi Qin Secretary, Director
Jiang Guo Liang Supervisors
Xu Jian Xin Director
Duan Hong Zhuan Executives
Chen Hai Yan Executives
Hong Da Cheng Director

China Resources Boya Bio-pharmaceutical Group Co Headlines

No Headlines